This randomized clinical study examined the use of hyaluronic acid to treat infrabony periodontal defects over a period of 24 months. Method and Materials: Forty subjects with a two-wall infrabony defect (probing depth [PD] ≥ 7 mm; clinical attachment level [CAL] ≥ 7 mm) were selected. The defects were randomly divided Into two groups: sites treated with hyaluronic acid (test group) and those treated with open flap debridement (control group). Results: The 12- and 24-month evaluations were based on clinical and radiographic parameters. The primary outcome variable was CAL. Test defects shows a mean CAL gain of 1.9 ± 1.8 mm, while the control defects yielded a significantly lower gain of 1.1 ±0.7 mm. PD reduction was also significantly higher in the test group (1.6 ± 1.2 mm) than In the control group (0.8 ± 0.5 mm). Frequency distribution analysis of the study outcomes Indicated that hyaluronic acid increased the predictability of clinically significant results (CAL gains ≥ 2 mm and PD reduction ≥ 2 mm) In the test group compared with the controls. Conclusions: The treatment of infrabony defects with hyaluronic acid offered an additional benefit In terms of CAL gain, PD reduction, and predictability compared to treatment with open flap debridement. © 2013 by Quintessence Publishing Co Inc.

Treatment of infrabony periodontal defects using a resorbable biopolymer of hyaluronic acid: A randomized clinical trial

Isola G.
Co-primo
Writing – Review & Editing
2013

Abstract

This randomized clinical study examined the use of hyaluronic acid to treat infrabony periodontal defects over a period of 24 months. Method and Materials: Forty subjects with a two-wall infrabony defect (probing depth [PD] ≥ 7 mm; clinical attachment level [CAL] ≥ 7 mm) were selected. The defects were randomly divided Into two groups: sites treated with hyaluronic acid (test group) and those treated with open flap debridement (control group). Results: The 12- and 24-month evaluations were based on clinical and radiographic parameters. The primary outcome variable was CAL. Test defects shows a mean CAL gain of 1.9 ± 1.8 mm, while the control defects yielded a significantly lower gain of 1.1 ±0.7 mm. PD reduction was also significantly higher in the test group (1.6 ± 1.2 mm) than In the control group (0.8 ± 0.5 mm). Frequency distribution analysis of the study outcomes Indicated that hyaluronic acid increased the predictability of clinically significant results (CAL gains ≥ 2 mm and PD reduction ≥ 2 mm) In the test group compared with the controls. Conclusions: The treatment of infrabony defects with hyaluronic acid offered an additional benefit In terms of CAL gain, PD reduction, and predictability compared to treatment with open flap debridement. © 2013 by Quintessence Publishing Co Inc.
Hyaluronic acid; Infrabony periodontal defect; Periodontal disease; Periodontal regeneration; Randomized clinical trial; Absorbable Implants; Adult; Aged; Alveolar Bone Loss; Analysis of Variance; Chi-Square Distribution; Double-Blind Method; Female; Humans; Hyaluronic Acid; Male; Middle Aged; Periodontal Debridement; Viscosupplements; Guided Tissue Regeneration, Periodontal; Medicine (all)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/345186
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 47
social impact